InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, shares results from early neurodegenerative disease studies demonstrating how specific cannabinoids induced neuroprotective effects and enhanced neuronal function.
Dr. Hsu talks about the nature of cannabinoids, how they interact with the body and what makes them attractive therapeutic targets for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease. He explains how specific cannabinoid analogs not only showed neuroprotective effects but promoted neurite outgrowth which may restore the function of these neurons.
This webinar “Exploring the Neuroprotective Qualities of Rare Cannabinoids” was hosted by John Heerdink of The Tribe Public on November 17, 2022.
InMed has selected to advance two cannabinoid analogs to in vivo studies of neurodegenerative disease.
Learn more about our neurodegenerative disease program.